glp-1 and kidneys receptor agonists in patients with chronic kidney disease either overweight or obesity Mechanisms of GLP-1 receptor–independent renoprotective

In 2023, Juan P Frias and colleagues, in The Lancet, published the first phase two clinical trial of orforglipron, which investigated the use of a small-molecule oral GLP-1R agonist called orforglipron in type 2 diabetes, which can be taken at any time of the day without restrictions on food and water intake (Frias et al., 2023)

Options vary in effectiveness, side effects, and suitability based on individual health needs and goals

Start With a Consultation Discuss your weight loss treatment options with our team by requesting a consultation using the online form, or call our office at (817) 228-4315 to schedule an appointment

[DOI] [PubMed] [Google Scholar] 8.Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD

Projected for late 2026 or early 2027, depending on trial results

Product packaging may differ from images shown